Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE.

Created on 25 Oct 2026

Authors

David Z I Cherney, Tae Won Yi, Hiddo J L Heerspink, Linong Ji, Janet B McGill, Peter Rossing, Katherine R Tuttle, Jesper N Bech, Paolo Fiorina, Albert Power, Karoline Schousboe, Nicholas M Selby, Emanuela Setola, J David Smeijer, Robert Lawatscheck, Meike Brinker, Julie Russell, Patrick Schloemer, Per-Henrik Groop, FINE-ONE Investigators23

Published in

Kidney international reports. Volume 11. Issue 11. Pages 107083. Epub Sep 16, 2026.

Abstract

The nonsteroidal mineralocorticoid receptor antagonist finerenone reduces urine albumin-to-creatinine ratio (UACR) in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This prespecified analysis evaluated acute changes in estimated glomerular filtration rate (eGFR) with finerenone and their impact on safety.
Adults with T1D and CKD (n = 242; eGFR ≥ 25-< 90 ml/min per 1.73 m2; UACR ≥ 200 to < 5000 mg/g) receiving stable renin-angiotensin system (RAS) inhibition were randomized 1:1 to finerenone or placebo. The primary outcome was acute change in eGFR (from baseline to month 1), termed "eGFR dip." Reversibility of eGFR change was assessed from end of the treatment (month 6) to follow-up (month 7). Change in eGFR was assessed across eGFR dip subgroups (eGFR > 0 to ≤ 10% decline, > 10% decline, and ≥ 0% increase) and prespecified characteristics (baseline eGFR, UACR, history of cardiovascular disease [CVD], and diuretic use).
Mean acute eGFR decline at month 1 was greater with finerenone (-2.78 ml/min per 1.73 m2 [95% confidence interval [CI], -4.15 to -1.40]) versus placebo (-0.78 ml/min per 1.73 m2; [95% CI, -2.22 to 0.66]); treatment difference was -1.99 ml/min per 1.73 m2 (95% CI, -3.97 to -0.01 [P = 0.049]). Placebo-corrected eGFR increased during the washout period across the groups. Acute eGFR changes did not differ according to prespecified characteristics. The incidence of treatment-emergent adverse events (TEAEs) was comparable across eGFR dip subgroups in both the treatment groups. Greater declines in eGFR were associated with greater reductions in UACR at month 3.
In people with T1D and CKD, finerenone induced an acute eGFR dip that was well tolerated without unexpected safety signals.

PMID:
42927222
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 20
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement